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OBJECTIVES: This study compared the effectiveness of rosuv-
astatin (RSV) to other statins prescribed in clinical practice in
prevention of fatal and non-fatal cardiovascular (CV) events.
METHODS: This longitudinal inception cohort study, conducted
using MedStat MarketScan research databases, included patients
aged 18 who started statin therapy during August 2003 to
December 2005. Patients were followed until 90 days after index
statin monotherapy exposure, an event, end of eligibility, or end
of study. The primary endpoint was a composite of CV death
(in-hospital only), myocardial infarction, unstable angina, coro-
nary revascularization, stroke, and carotid revascularization.
Adjusted time-to-event analyses incorporating a propensity score
covariate were used, and analyses were stratiﬁed by duration of
statin exposure. RESULTS: Among 395,039 patients who met
inclusion/exclusion criteria, 12% initiated rosuvastatin (RSV),
and 9,622 (2.4%) experienced an outcome event (3.7 per 100
person-years). The median (mean) duration of statin treatment
and follow-up was 100 (180) days and 180 (242) days, respec-
tively. Although no statistically signiﬁcant difference in CV
event rates between RSV and other statins was observed after
adjustment for demographics and medical/prescription history
(HR = 0.99, 95% CI = 0.93–1.06), a trend toward increased
beneﬁt was seen with longer exposure time with RSV compared
to “other statins” (90 days exposure, HR = 0.97, 95%
CI = 0.86–1.09; 180 days, HR = 0.91, 95% CI = 0.78–1.06;
270 days, HR = 0.80, 95% CI = 0.64–1.00; 360 days,
HR = 0.88, 95% CI = 0.65–1.19). Other study end-points, strati-
ﬁcations, and comparisons with speciﬁc statin drugs were evalu-
ated. CONCLUSION: Primary analysis showed similar incidence
rates of CV-related events in a clinical practice setting between
the statin cohorts over a median of 180 days of follow-up. With
longer exposure times, a trend of a decreased CV event rate with
RSV as compared to other statins was found. These ﬁndings are
consistent with a beneﬁcial effect of aggressive LDL lowering
treatment in a clinical practice setting.
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OBJECTIVES: The increasing number of clinical trials in hyper-
tension provides data to inform more effective treatment strate-
gies, but partly generate contradicting results. Synthesis of
individual trial data using meta-analytic techniques ensures more
reliable estimates on treatment outcomes. To compare the anti-
hypertensive efﬁcacy of telmisartan 40 and 80 mg, against all
other available drugs in this class (AIIA) by undertaking a meta-
analysis of individual randomised controlled trials. METHODS:
Two distinct approaches were followed. Direct comparison of the
efﬁcacy of telmisartan versus other AIIA therapies using evidence
from studies performed head to head, and indirect comparison
using placebo as common comparator. Fixed and random effects
meta-analyses were conducted for all comparisons. The studies
used reported trough measurements. RESULTS: Direct compari-
sons of telmisartan 40 mg versus losartan 50 mg on diastolic and
systolic blood pressure reduction showed a greater and signiﬁ-
cant effect for telmisartan. Indirect comparisons showed a
greater and signiﬁcant effect in both trough DBP/SBP versus all
other AIIA except candesartan where no signiﬁcant difference
was obtained. In particular, telmisartan 40 mg reduced 24-h DBP
by 7.3  0.7 compared to: valsartan 80 mg 4.7  5.7 (95% CI
between tx diff: -4.33, -0.80); irbesartan 150 mg 5.2  6.7
(95% CI between tx diff: -4.23, -0,003); losartan 50 mg
4.2  5.5 (95%CI between tx diff: -5.09, -1.10); candesartan
8 mg 5.8  8.0 (95% CI between tx diff: -3.99, 1.14). Similarly,
when comparing higher doses of the drugs, telmisartan 80 mg
results in greater and signiﬁcant reductions in both trough DBP
and SBP than losartan 100 mg and valsartan 160 mg, as well as
with irbesartan 300 mg and candesartan 16 mg but with no
statistical signiﬁcance. CONCLUSION: Overall, in the mono-
therapy studies both low and high dose telmisartan has an advan-
tage in reducing blood pressure over the other drugs of the class.
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OBJECTIVES: To compare the clinical effectiveness of eprosar-
tan and irbesartan, losartan, telmisartan and valsartan in patients
with hypertension. METHODS: The clinical effectiveness analy-
sis in accordance with the Cochrane Collaboration guidelines
were performed. Only head-to head study with randomization
were include to analysis. RESULTS: Eprosartan vs losartan- One
RCT (head-to-head) was identify. There was no statistically sig-
niﬁcant difference between groups in change in systolic and dias-
tolic pressure. Also there was no statistically signiﬁcantly more
patients achieved clinical response after 4 weeks follow-up. The
incidence of adverse events were similar in both group. Eprosa-
rtan vs telmisartan- Analysis based on direct evidence (one RCT)
showed statistically important difference in change diastolic pres-
sure after 12 month, favors telmisartan: RD: 4 mmHG (95% CI:
3.51; 4.49). There was no statistically differences between com-
pared groups in change in systolic pressure. Frequency of adverse
events was also comparable between groups. Eprosartan vs val-
sartan or irbesartan: Because of lack of relevant study (head to
head), analysis could not be performed. CONCLUSION: Analy-
sis suggests that eprosartan has comparable efﬁcacy to losartan.
Telmisatran is more effective, compared with eprosartan, for
treatment of patients with hypertension. Safety of interventions
are similar.
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OBJECTIVES: To compare the efﬁcacy of rosuvastatin 40 mg
with 20 mg for treatment of hypercholesterolaemia and estimate
the associated impact on ﬁnal outcomes based on a meta-analysis
of 9 randomised controlled trials (RCTs) from the CRESTOR
clinical trial programme. METHODS: A regression analysis of
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